Zhoushan Tian - Sino Biopharmaceutica President
| SBMFF Stock | USD 0.42 0.00 0.00% |
President
Mr. Tian Zhoushan serves as Executive Director of the Company. joined the Group in April, 1997 and is responsible for the business of NJCTT. Mr. Tian is currently the general manager of NJCTT since 2015.
| Age | 59 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 852 2802 9886 |
| Web | https://www.sinobiopharm.com |
Sino Biopharmaceutica Management Efficiency
The company has return on total asset (ROA) of 0.0451 % which means that it generated a profit of $0.0451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2908 %, meaning that it generated $0.2908 on every $100 dollars invested by stockholders. Sino Biopharmaceutica's management efficiency ratios could be used to measure how well Sino Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Ella Sorani | BioLineRx | 57 | |
| George Avgerinos | Fortress Biotech Pref | 69 | |
| Kyle Wool | Dominari Holdings | 47 | |
| Holly MBA | BioLineRx | 63 | |
| David McClung | Biocardia | 62 | |
Management Performance
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 |
Sino Biopharmaceutical Leadership Team
Elected by the shareholders, the Sino Biopharmaceutica's board of directors comprises two types of representatives: Sino Biopharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sino. The board's role is to monitor Sino Biopharmaceutica's management team and ensure that shareholders' interests are well served. Sino Biopharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sino Biopharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Cheung Cheng, Executive Director and Member of Executive Board Committee | ||
| Fai Chia, Assistant to the Chairman, Personnel Manager | ||
| Wei Ye, Assistant President Deputy General Manager - R&D Department | ||
| Ping Tse, Founder and President Compliance Officer, Executive Director, Member of Executive Board Committee and Member of Nomination Committee | ||
| Mingqin Li, Vice President Director and Deputy General Manager of CTGC and the director of Beijing Tide | ||
| Wun Tse, Assistant to the Chairman | ||
| Zhoushan Tian, Vice President of JCTT and General Manager of NJCTT | ||
| Y Tse, Executive Chairman of the Board | ||
| Hsin Tse, VP, General Manager of Audit Department, Executive Director and Member of Executive Board Committee | ||
| Eric Tse, CEO Director |
Sino Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sino Biopharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Profit Margin | 0.29 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 10.34 B | |||
| Shares Outstanding | 18.81 B | |||
| Shares Owned By Insiders | 47.86 % | |||
| Shares Owned By Institutions | 14.86 % | |||
| Price To Earning | 24.17 X | |||
| Price To Book | 2.51 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Sino Pink Sheet
Sino Biopharmaceutica financial ratios help investors to determine whether Sino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sino with respect to the benefits of owning Sino Biopharmaceutica security.